Status:
COMPLETED
Evaluation of Biomarker Expression in Diabetic and Healthy Subjects Over a One Year Period
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 1
Eligibility:
All Genders
14-40 years
Brief Summary
This study is conducted in the United States of America (USA). The aim of this study is to assess longitudinal variation of immune biomarkers in subjects with type 1 diabetes (T1D), type 2 diabetes (T...
Eligibility Criteria
Inclusion
- T1D
- Male or female subjects diagnosed within the last 3 years and with good general health based on medical history
- Age above or equal to 14 years and below or equal to 40 years
- Body weight above 45 kg
- T2D
- Male or female subjects diagnosed within the last 15 years with good general health based on medical history
- HbA1c between 6.5% and 10%
- Body mass index (BMI) below 45 kg/m\^2
- Age above or equal to 18 and below 65 years
- On insulin treatment
- HS
- Male or female subjects with good general heath based on medical history
- Age above or equal to 18 years and below or equal to 40 years
Exclusion
- Any chronic disorder (besides T1D or T2D) or severe disease which, in the opinion of the investigator, might jeopardize subject's safety or compliance with the protocol
- Female of child-bearing potential who is pregnant, breast-feeding, or intends to become pregnant
Key Trial Info
Start Date :
July 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2015
Estimated Enrollment :
61 Patients enrolled
Trial Details
Trial ID
NCT01900834
Start Date
July 1 2013
End Date
October 1 2015
Last Update
October 10 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Princeton, New Jersey, United States, 08540